受注:045-509-1970 |
技術サポート:[email protected] 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
Synonyms | Argatroban hydrate, Argipidine,MCI-9038 Monohydrate | Storage (From the date of receipt) |
3 years -20°C powder 1 years -80°C in solvent |
||||
化学式 | C23H36N6O5S.H2O |
||||||
分子量 | 526.65 | CAS No. | 141396-28-3 | ||||
Solubility (25°C)* | 体外 | DMSO | 100 mg/mL (189.87 mM) | ||||
Ethanol | 40 mg/mL (75.95 mM) | ||||||
Water | Insoluble | ||||||
体内 (毎回新しく調製した物を用意してください) |
|
||||||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
製品説明 | Argatroban (Argatroban hydrate, Argipidine,MCI-9038 Monohydrate) is a direct, selective thrombin inhibitor with anticoagulant effects. |
---|---|
in vitro | Argatroban is highly selective for thrombin and has little or no effect on related serine proteases (trypsin, factor Xa, plasmin, and kallikrein). Argatroban is effective against free, fibrin-bound and clot-bound thrombin with comparable half-maximal inhibitory concentrations (IC50), and argatroban is also effective in inhibiting platelet aggregation and thromboxane generation in the presence of both free and clot-bound thrombin[1]. Argatroban binds thrombin and inhibits its activity without the requirement of coenzymes, unlike antithrombin III or heparin cofactor II. Argatroban decreases bone metastasis of B16 mouse melanoma cells by inactivating thrombin activity. Moreover, argatroban has potential to inhibit PAR-2 activation by interfering with the thrombogenic cycle. It does not have toxic effect for tumor cells[2]. |
in vivo | Within a clinically relevant dose range (from 1–3 μg/kg/min in prevention or treatment of thrombotic events in HIT to up to 25 μg/kg/min in PCI in HIT patients), argatroban exhibits linear pharmacokinetic behavior, and steady state levels are attained within 1 hour after the start of an infusion. The elimination half-life of argatroban in healthy subjects is about 45 minutes, with a corresponding decline in its anticoagulant effects which reach their pretreatment level within 2–4 hours after cessation of an infusion. Argatroban lacks major drug–drug interactions with CYP3A4/5 inhibitors such as erythromycin or with acetaminophen, warfarin, and digoxin. However, in patients with hepatic impairment, area under the concentration versus time curve (AUC), maximum concentration, and half-life of argatroban were increased approximately 2- to 3-fold, and clearance was one-fourth that of healthy volunteers. The increase in plasma concentrations in these patients coincided with increased pharmacodynamic effects[1]. |
細胞アッセイ | 細胞株 | MDA-231 breast cancer cells |
---|---|---|
濃度 | 0.1-1 μM | |
反応時間 | 4 h | |
実験の流れ | Tissue factor (TF) activity was measured as factor X (FX) activation by the factor VIIa (FVIIa)/TF complex on MDA-231 cells. MDA-231 cells were starved in serum-free medium for 24 h, following incubation with FBS for 24 h (24-well plate, 2.0 × 105 cells/well). After starvation, MDA-231 cells were treated with thrombin (0.1-10 U/ml) in presence or absence of argatroban (0.1-1 μM) for 4 h. |
|
動物実験 | 動物モデル | Mice that were injected with MDA-231 breast cancer cells into the left heart ventricle |
投薬量 | 9 mg/kg/day | |
投与方法 | i.p. |
|
Tissue factor-induced fibrinogenesis mediates cancer cell clustering and multiclonal peritoneal metastasis [ Cancer Lett, 2023, 553:215983] | PubMed: 36404569 |
Thrombin inhibitor argatroban modulates bone marrow stromal cells behaviors and promotes osteogenesis through canonical Wnt signaling [ Life Sci, 2021, 269:119073] | PubMed: 33460666 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。